Beyond Clinical Trials: Real-World Evidence in Life Sciences

Life sciences organizations were built around a familiar rhythm. Clinical teams framed a question, trials produced answers, and evidence moved toward a decision point that felt discrete and bounded.

That rhythm still matters, and clinical trials still carry the weight they always have. The pressure now comes from everything that happens after approval, and sometimes even alongside it, when regulators, payers, and health systems seek evidence that reflects how therapies perform in the real world.

Real-world evidence, often shortened to RWE, has evolved from a supporting evidence source into a critical component of evidence generation. Much of the early focus was on accessing real-world data and developing robust analytical approaches. While those challenges remain, the primary focus is increasingly shifting toward an organization's ability to generate trustworthy evidence consistently and at scale. The operational implications of this shift are now being felt across R&D, safety, and regulatory teams.

A common scenario is a therapy earning approval, with the expectation that the most intensive phase of evidence generation is complete, only for a payer to request outcomes data in a broader population before expanding reimbursement. This may occur while a regulator simultaneously requires additional post-market evidence on a shorter timeline than anticipated.

In this environment, success depends as much on operational readiness as on scientific rigor.

Why Real-World Evidence Is Reshaping What Counts as Evidence Generation 

Targeted therapies continue to narrow trial populations, which leaves more unanswered questions once the product reaches diverse real-world populations. Real-world data, often shortened to RWD, can help fill those gaps when thoughtfully designed observational studies and monitoring programs extend the evidence base.

Reimbursement scrutiny has also intensified. Payers increasingly want to see effectiveness in routine care settings, not only efficacy under controlled trial conditions, and those conversations increasingly turn on real-world evidence that is defensible enough to stand up to questioning.

Regulatory flexibility adds another layer. Pathways that support earlier or progressive access can create more routes to market, while also increasing the obligation to keep producing evidence after approval. EMA's broader efforts to advance the use of real-world evidence, alongside concepts such as adaptive pathways that combine earlier access with continued evidence generation, reflect how regulators are increasingly formalizing expectations for evidence generation beyond the trial phase.

Continuous streams of patient data from electronic health records, registries, claims data, and wearables keep generating signals long after any controlled study ends, whether organizations are ready to use them or not.

Together, these factors mean that the nature of evidence generation is no longer limited to clinical trials. It becomes a continuous organizational capability that needs to operate at pace, across sources, and under steady scrutiny.

Real-World Data Creates Operational Requirements, Not Just New Study Designs

RWE rarely falls short because leaders do not understand what evidence is needed. Most teams have a clear view of the questions they will face across the lifecycle.

The harder challenge lies a little deeper. Continuous evidence requires an operating model that can generate, manage, interpret, and defend RWE over time, which puts a new load on data governance, biostatistics, medical writing, pharmacovigilance, and regulatory operations. 

The following four shifts tend to separate organizations that keep up from those that feel permanently behind.

Data Traceability Turns RWD Into Defensible Real-World Evidence 

RWD can come from many places, and the variety is part of the value. The same variety becomes a risk when evidence needs to be defended.

Retrospective studies and longitudinal monitoring only hold up when underlying data is traceable, clean, and explainable across systems and timelines. Many organizations still store clinical, real-world, and administrative data in separate environments with different owners, different definitions, and different controls. That separation creates friction when an RWE program needs to prove lineage, handle missingness transparently, and show that data handling did not bias the outcome.

FDA guidance on submissions using real-world data and real-world evidence reinforces how much attention goes to the quality and context of RWD when it supports labeling or regulatory decisions.

Practically, data traceability becomes less about one integration project and more about repeatable governance, including:

• Consistent definitions for key variables across sources
• Clear lineage and audit trails from ingestion through analysis
• Transparent handling of missing data, transformations, and exclusions
• Documentation that stays aligned as data refreshes and cohorts evolve

When traceability is weak, the organization spends more time defending the credibility of its data than demonstrating the value of its findings.

Biostatistics and Medical Writing Become Continuous Evidence Generation Functions

Many teams still treat statistical analysis and medical writing as activities that peak at submission. RWE changes that cadence because observational studies, post-market surveillance activities, and comparative effectiveness research operate on rolling timelines.

The work becomes ongoing, and it also becomes more cross-functional. A real-world evidence program needs statistical rigor that fits the study design, and it needs documentation that can be reviewed by regulators and questioned by payers without collapsing into back-and-forth rework.

That shift often changes how teams staff and operate. Instead of ramping up late, the organization needs steady-state capacity that can iterate, update, and respond as new RWD sources come online and new questions emerge.

Pharmacovigilance Becomes a Front-Line Real-World Evidence Capability

Long-term safety monitoring used to be treated as a compliance obligation that ran alongside commercial execution. RWE makes pharmacovigilance feel closer to the core of the lifecycle strategy.

Signals in the post-market environment feed back into label discussions, payer conversations, and clinical positioning. Teams that treat pharmacovigilance as a back-office activity can find themselves exposed, especially when safety narratives become public before the organization has a coherent, evidence-backed response.

Guidance such as ICH E2E emphasizes structured planning for pharmacovigilance activities in the postmarketing period, which aligns with the idea that ongoing monitoring needs to be designed, not improvised. 

Regulatory Documentation Becomes a Living System for RWE and RWD

When evidence becomes continuous, regulatory documentation has to keep pace. CTDs, risk management plans, safety updates, and supporting narratives move on shorter cycles, and those cycles can compress quickly when regulators request additional evidence.

EMA’s efforts to develop guidance and a roadmap around real-world evidence reflect the direction of travel, and it also signals that expectations will become more structured over time.

The pressure point is rarely a single submission. The pressure point is sustained iteration, which requires tools, workflows, and teams that can maintain consistency across updates without slowing down. 

At that point, the core observation becomes clear. The challenge is not only scientific, it’s also structural. Organizations know what evidence they need, and the harder question is whether their operating model can generate it continuously. 

Real-World Evidence as an Operating Requirement

Organizations navigating this transition most effectively do not treat RWE as a new project that sits beside clinical work. Instead, they treat it as a standing operating requirement, and they build the connected capability to match, spanning data governance, data traceability, biostatistics, medical writing, pharmacovigilance, and regulatory documentation.

For many teams, the shift triggers practical decisions about what to build in-house, what to partner on, and how to connect functions so they can generate trustworthy evidence consistently and at scale throughout the product lifecycle. 

These are the operational questions our global Lifesciences & Healthcare teams work through with leading organizations every day, and we’ll explore these in upcoming blog posts.

If you want context on how this connects to the broader patient-centric operating model, you can read our first article in this series here.

If you want to follow the rest of the series as it publishes, you can explore our blog posts and insights here.